KCNE5: A Promising Drug Target and Biomarker for Kentucky Type Neuronopathy

Target Name: KCNE5

NCBI ID: G23630

KCNE5

Other Name(s): KCNE5_HUMAN | Potassium voltage-gated channel subfamily E regulatory beta subunit 5 | Potassium voltage-gated channel subfamily E member 1-like protein | potassium voltage-gated channel subfamily E member 1-like protein | KCNE1-like | KCNE1L | potassium voltage-gated channel, Isk-related family, member 1-like | Cardiac voltage-gated potassium channel accessory subunit 5 | AMME syndrome candidate gene 2 protein | Potassium voltage-gated channel subfamily E regulatory subunit 5 | potassium channel subunit beta MiRP4 | AMMECR2 | cardiac voltage-gated potassium channel accessory subunit 5 | Potassium channel subunit beta MiRP4 | potassium voltage-gated channel subfamily E regulatory subunit 5 | Voltage-gated potassium channel accessory subunit 5 | AMMECR2 protein

KCNE5: A Promising Drug Target and Biomarker for Kentucky Type Neuronopathy

Introduction

Kentucky type neuron loss syndrome (KCNFS) is a hereditary neurodegenerative disease in which 50% of the neurons in the brain are lost. The disease usually presents in early childhood, causing patients to lose independence and quality of life. Currently, there are no specific drugs to treat KCNFS, and the pathophysiological mechanisms of this disease remain unclear. Therefore, studying new drug targets and biomarkers is of great significance for the treatment of KCNFS.

KCNE5: a potential drug target

KCNE5 is a potassium channel that plays a key role in the normal function of neurons. Research shows that KCNE5 plays a key role in neuronal death and synaptic plasticity. In addition, KCNE5 also plays an important role in the electrophysiological activity of neurons. Therefore, KCNE5 has become a potential drug target.

Currently, a variety of drugs use KCNE5 as a target when treating KCNFS, including anti-neuron death drugs, anti-neuron synaptic plasticity drugs, and anti-neuron ion channel drugs. These drugs have shown efficacy against KCNFS in animal models, but their effectiveness in human clinical trials is unclear. Therefore, further investigation of the role of KCNE5 in humans is crucial.

KCNE5 as a biomarker

KCNE5's role in neuronal death and synaptic plasticity makes it an attractive target for studying neurodegenerative diseases. In addition, due to its important role in neuronal electrophysiological activity, KCNE5 has also become a potential biomarker. By detecting the levels of KCNE5, the degree of neuronal damage can be assessed and provide new methods for the diagnosis of neurodegenerative diseases.

Research methods

Currently, two methods are usually used to study the role of KCNE5: calcium ion imaging technology and immunohistochemistry technology.

1. Calcium ion imaging technology

Calcium imaging is a widely used technique for detecting neuronal death and synaptic plasticity. In this technique, changes in calcium ion concentration are used to visualize changes in neuronal activity. By observing changes in calcium ion concentration in neuronal activity, the health of neurons can be assessed and the number of dead neurons can be determined.

2. Immunohistochemistry

Immunohistochemistry is a technique that detects protein expression in tissues. By using specific antibodies to detect the expression levels of KCNE5 protein in neurons, the health of neurons can be assessed and the number of neuronal deaths can be determined.

in conclusion

KCNE5 is a potential drug target and plays an important role in neuronal death and synaptic plasticity. In addition, KCNE5 is also a potential biomarker for neurodegenerative diseases. With further research, KCNE5 is expected to become a first-line drug for the treatment of KCNFS and provide a new method for the diagnosis of neurodegenerative diseases.

Protein Name: Potassium Voltage-gated Channel Subfamily E Regulatory Subunit 5

Functions: Potassium channel ancillary subunit that is essential for generation of some native K(+) currents by virtue of formation of heteromeric ion channel complex with voltage-gated potassium (Kv) channel pore-forming alpha subunits. Functions as an inhibitory beta-subunit of the repolarizing cardiac potassium ion channel KCNQ1

The "KCNE5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNE5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets